The zoonotic antivirals market is projected to grow from USD 2.5 billion in 2026 to USD 6.6 billion by 2036, at a CAGR of 10.2%. Broad-spectrum antivirals will dominate with a 48.0% market share, while emerging zoonoses will lead the applications segment with a 56.0% share.